BPC-157 references: tendon, vessel and human studies
The tendon paper, the vessel experiment and the human reports are worth opening separately. They are not interchangeable kinds of support.
Three useful places to start
For the physical repair claim, start with Staresinic and colleagues’ rat Achilles study. For the proposed mechanism, open Hsieh and colleagues’ VEGFR2 experiments. For the human-data gap and replication concern, read McGuire and colleagues’ 2025 review.
The tendon experiment rewards a return visit because strength and organization were measured alongside function. The human reports on knee pain, interstitial cystitis and intravenous safety ask much smaller questions than the compound's reputation suggests.
The regulatory entries below address another argument entirely. A biological result cannot settle a pharmacy rule, and an FDA table cannot establish that a tendon healed.
Looking for a PMC7992657 citation?
This list has no entry with the identifier PMC7992657. Without a matching title or author, I cannot identify it as a BPC-157 source from these records alone. The citations below provide the paper titles and available DOI or PubMed identifiers for the studies discussed here.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
- Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. ↗
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. ↗
- Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41. ↗
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. ↗
- Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. ↗
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
- McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
- Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
- Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 entry; list update effective September 29, 2023). ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; enforcement-discretion policy). ↗
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance; bulks-list nomination and PCAC framework). ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda listing BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List). ↗
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (503A patient-specific compounding and 503B outsourcing-facility pathway; ingredient-eligibility requirements). ↗
- McDermott Will & Emery. End of an Era: FDA Retires 2017 Interim Policies for Bulk Drug Lists (legal analysis of the January 7, 2025 FDA action). ↗
- World Anti-Doping Agency. The Prohibited List (BPC-157 falls under the S0 non-approved-substances category, prohibited at all times in sport). ↗
- Author group (2025) BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025. 18:1450. ↗
- Tohyama Y, et al. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004. 76:345-357. ↗
- Boban Blagaic A, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005. 512:173-179. ↗